[Federal Register Volume 88, Number 78 (Monday, April 24, 2023)]
[Notices]
[Pages 24823-24824]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-08564]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Therapeutics Development for Opioid 
Use Disorder in Patients with Co-occurring Mental Disorders (UG3/
UH3).
    Date: May 23, 2023.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific 
Review Officer, Division of Extramural Research, Scientific Review 
Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet 
Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702, 
[email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Developed Regulated Therapeutic and Diagnostic 
Solutions for Patients Affected by Opioid and/or Stimulants Use 
Disorders.
    Date: June 1, 2023.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Shareen Amina Iqbal, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 443-4577, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; BRAIN Initiative: Brain-Behavior Quantification and 
Synchronization--Transformative and Integrative Models of Behavior 
at the Organismal Level.
    Date: June 5, 2023.
    Time: 11:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Research, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; BRAIN Initiative: Brain-Behavior Quantification and 
Synchronization--Transformative and Integrative Models of Behavior 
at the Organismal Level.
    Date: June 7, 2023.
    Time: 11:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Research, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 
6021, Bethesda, MD 20892, (301) 594-9460, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Functional Validation and/or Characterization of 
Genes or Variants Implicated in SUD.
    Date: June 5, 2023.
    Time: 11:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Division of Extramural Research, 
National Institute on Drug Abuse, NIH, Bethesda, MD 20892, (301) 
827-4471, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Preventing Opioid Misuse and Co-
Occurring Conditions by Intervening on Social Determinants (R01).
    Date: June 8, 2023.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Marisa Srivareerat, Ph.D., Scientific Review 
Officer, Scientific Review Branch, Office of Extramural Policy, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC 6021, Bethesda, MD 20892, (301) 435-1258, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist

[[Page 24824]]

Development Award for Clinicians, Scientist Development Awards, and 
Research Scientist Awards; 93.278, Drug Abuse National Research 
Service Awards for Research Training; 93.279, Drug Abuse and 
Addiction Research Programs, National Institutes of Health, HHS)

    Dated: April 18, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-08564 Filed 4-21-23; 8:45 am]
BILLING CODE 4140-01-P